(NASDAQ: PYXS) Pyxis Oncology's forecast annual revenue growth rate of -13.82% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.37%.
Pyxis Oncology's revenue in 2025 is $16,146,000.On average, 1 Wall Street analysts forecast PYXS's revenue for 2027 to be $739,084,980, with the lowest PYXS revenue forecast at $739,084,980, and the highest PYXS revenue forecast at $739,084,980. On average, 1 Wall Street analysts forecast PYXS's revenue for 2028 to be $4,496,100,295, with the lowest PYXS revenue forecast at $4,496,100,295, and the highest PYXS revenue forecast at $4,496,100,295.
In 2029, PYXS is forecast to generate $7,346,812,653 in revenue, with the lowest revenue forecast at $2,691,501,136 and the highest revenue forecast at $12,002,124,171.